scholarly journals Effects of Docosahexaenoic Acid Supplementation on Blood Pressure, Heart Rate, and Serum Lipids in Scottish Men with Hypertension and Hypercholesterolemia

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Miki Sagara ◽  
Marina Njelekela ◽  
Takanori Teramoto ◽  
Takashi Taguchi ◽  
Mari Mori ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Docosahexaenoic Acid ◽  
Disease Risk ◽  
Density Lipoprotein ◽  
Double Blind ◽  
Risk Factor Level ◽  
Disease Risks

To investigate the effects of daily supplementation with docosahexaenoic acid (DHA) on coronary heart disease risks in 38 middle-aged men with hypertension and/or hypercholesterolemia in Scotland, a five-week double-blind placebo-controlled dietary supplementation with either 2 g of DHA or active placebo (1 g of olive oil) was conducted. Percent composition of DHA in plasma phospholipids increased significantly in DHA group. Systolic and diastolic blood pressure and heart rate decreased significantly in DHA group, but not in placebo group. High-density lipoprotein cholesterol (HDL-C) increased significantly, and total cholesterol (TC)/HDL-C and non-HDL-C/HDL-C ratios decreased significantly in both groups. There was no change in TC and non-HDL-C. We conclude that 2 g/day of DHA supplementation reduced coronary heart disease risk factor level improving blood pressure, heart rate, and lipid profiles in hypertensive, hypercholesterolemic Scottish men who do not eat fish on a regular basis.

Relationships between hostility and physiological coronary heart disease risk factors in young adults: the moderating influence of depressive tendencies

2000 ◽  
Vol 30 (2) ◽  
pp. 381-393 ◽  
Author(s):  
N. RAVAJA ◽  
T. KAUPPINEN ◽  
L. KELTIKANGAS-JÄRVINEN
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Young Adults ◽  
Heart Disease ◽  
Disease Risk ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Chd Risk ◽  
Chd Risk Factors

Background. We examined whether the relationships between hostility and physiological coronary heart disease (CHD) risk factors differ as a function of depressive tendencies (DT).Methods. The participants were 672 randomly selected healthy young adults who self-reported their hostility (anger, cynicism, and paranoia) and DT. The physiological CHD risk factors studied were systolic blood pressure, diastolic blood pressure, body-mass index, serum high-density lipoprotein cholesterol, serum low-density lipoprotein cholesterol and serum triglycerides.Results. We found that hostility was negatively associated with the physiological CHD risk factors among individuals exhibiting high DT while hostility was positively associated with, or unrelated to, the physiological risk factors among individuals showing low DT. The Hostility × DT interaction explained 2 to 5% of the variance in the physiological parameters.Conclusion. The findings suggest that DT have a moderating influence on the relationships between hostility and CHD risk. Despite the established risk factor status of hostility, lack of anger and hostility, when combined with high DT, may represent the most severe exhaustion where the individual has given up. Disregard of this fact may explain some null findings in the research on hostility and CHD risk.

scholarly journals Hypertension and coronary artery disease in non-insulin dependent diabetes--cause and effect?

1992 ◽  
Vol 3 (4) ◽  
pp. S126
Author(s):  
J S Yudkin
Keyword(s):  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Disease Risk ◽  
Linear Increase ◽  
Randomized Controlled Studies ◽  
Patients With Diabetes ◽  
Insulin Dependent ◽  
Artery Disease ◽  
Log Linear

There is a log-linear increase in the risk of coronary heart disease with elevation of levels of blood pressure. Allowing for the phenomenon of regression dilution bias, this corresponds to around a 20 to 25% increase in risk for each 5 to 6 mm Hg elevation in usual diastolic blood pressure. In diabetic subjects, a similar relationship occurs, but of somewhat lesser degree. Recent overviews of therapy suggest that in nondiabetics, reducing blood pressure reverses around 50% of the excess coronary heart disease risk, but this has not yet been conclusively shown in patients with diabetes. The reduction in risk with therapy is a prerequisite to defining the antecedent as a causal influence on outcome, but it is as likely that the incomplete reversibility of excess risk represents other pathways of connection between hypertension and coronary heart disease as a consequent of iatrogenic effects of current treatments. Several alternative mechanisms are outlined, and the suggestion is made that only in the context of randomized controlled studies could the possible benefits on coronary heart disease of agents influencing such mechanisms be assessed.

Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B

2004 ◽  
Vol 42 (1) ◽  
Author(s):  
Valentine C. Menys ◽  
Yifen Liu ◽  
Michael I. Mackness ◽  
See Kwok ◽  
Muriel J. Caslake ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Heart Disease Risk ◽  
Apolipoprotein B ◽  
Disease Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Heart Disease Risk

AbstractSmall-dense low-density lipoprotein (SD-LDL) is associated with coronary heart disease risk. Current methods for its quantification are expensive, complex and time-consuming. Plasma was adjusted to a density (D) of 1.044 g/ml in a volume of 0.18 ml and centrifuged in a Beckman Airfuge at 160 000×

A Comparison of Atenolol and Long-Acting Trimazosin in Mild to Moderate Essential Hypertension

1985 ◽  
Vol 30 (2) ◽  
pp. 106-110 ◽  
Author(s):  
D. J. Webb ◽  
M. J. Hutcheson ◽  
M. P. Robertson ◽  
G. D. Murray ◽  
A. R. Lorimer ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Moderate Hypertension ◽  
Diastolic Pressure ◽  
Substantial Reduction ◽  
Density Lipoprotein ◽  
Double Blind ◽  
Randomised Study ◽  
Lipoprotein Concentration ◽  
Long Acting

In a 12-week double-blind randomised study the efficacy of atenolol and a new longer-acting formulation of trimazosin were compared when given once daily in patients with mild to moderate hypertension. Two parallel groups, each consisting of 18 patients, were studied. At randomisation the two groups were well matched for age and sex distribution. They were also well matched for blood pressure, pulse rate and body weight; these latter measurements were recorded at regular intervals during the 12 weeks of study. Atenolol produced substantial reduction in both systolic and diastolic blood pressure, and in heart rate, during 12 weeks of treatment. This therapeutic effect was maintained until the next dose after 24 hours. Trimazosin, by comparison, failed to reduce either systolic or diastolic pressure, or to alter heart rate. Side effects were minor with both agents and compliance with treatment was good. Atenolol caused significant elevation of plasma concentration of triglyceride, with reduction in high density lipoprotein concentration when compared with trimazosin. In conclusion, atenolol was confirmed as an effective agent for the treatment of mild to moderate hypertension. By comparison trimazosin in the longer-acting formulation was ineffective in this study. However, trimazosin may still find a place in treatment if used at higher dose.

Effect of soluble-viscous dietary fibre on coronary heart disease risk score across 3 population health categories: data from randomized, double-blind, placebo-controlled trials

2020 ◽  
Vol 45 (7) ◽  
pp. 801-804
Author(s):  
Vladimir Vuksan ◽  
John L. Sievenpiper ◽  
Elena Jovanovski ◽  
Alexandra L. Jenkins ◽  
Allison Komishon ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Risk Score ◽  
Coronary Heart Disease Risk ◽  
Disease Risk ◽  
Blood Cholesterol ◽  
Double Blind ◽  
Framingham Risk ◽  
Heart Disease Risk

We applied the Framingham risk equation in healthy, metabolic syndrome, and diabetes populations, following treatment with viscous fibre from konjac-based blend (KBB). KBB yielded reduction in estimated risk score by 16% (1.04 ± 0.03 vs. 0.87 ± 0.04, p < 0.01) in type 2 diabetes, 24% (1.08 ± 0.01 vs. 0.82 ± 0.02, p < 0.01) in metabolic syndrome, and 25% (1.09 ± 0.05 vs. 0.82 ± 0.06, p < 0.01) in healthy individuals. Drivers for decreased risk were improvements in blood cholesterol and systolic blood pressure. The composite coronary heart disease risk across populations was reduced 22% (p < 0.01). Novelty Viscous fibre from konjac-xanthan reduced 10-year relative coronary heart disease using Framingham Risk Score across the glycemic status spectrum.

Sign in / Sign up

Export Citation Format

Share Document